Related Experiment Video
Updated: Jun 29, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation
Karolina I Pellot Ortiz1, Julian S Rechberger2,3, Leo F Nonnenbroich2,4,5
1Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Inhibition of the interaction between MDM2 and p53 has emerged as a promising strategy for combating cancer, including the treatment of glioblastoma (GBM). Numerous MDM2 inhibitors have been developed and are currently undergoing rigorous testing for their potential in GBM therapy. Encouraging results from studies conducted in cell culture and animal models suggest that MDM2 inhibitors could effectively treat a specific subset of GBM patients with wild-type TP53 or functional p53. Combination therapy with clinically established treatment modalities such as radiation and chemotherapy offers the potential to achieve a more profound therapeutic response. Furthermore, an increasing array of other molecularly targeted therapies are being explored in combination with MDM2 inhibitors to increase the effects of individual treatments. While some MDM2 inhibitors have progressed to early phase clinical trials in GBM, their efficacy, alone and in combination, is yet to be confirmed. In this article, we present an overview of MDM2 inhibitors currently under preclinical and clinical investigation, with a specific focus on the drugs being assessed in ongoing clinical trials for GBM patients.
Insights
MDM2 inhibitors show promise for treating glioblastoma (GBM) by targeting the MDM2-p53 interaction. Clinical trials are evaluating their efficacy alone and in combination therapies for specific GBM patient subsets.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- The interaction between MDM2 and p53 is a validated target for cancer therapy.
- Glioblastoma (GBM) is an aggressive brain tumor where p53 pathway dysregulation is common.
- MDM2 inhibitors offer a novel therapeutic strategy for cancers, including GBM.
Purpose of the Study:
- To review MDM2 inhibitors in preclinical and clinical development for glioblastoma.
- To highlight MDM2 inhibitors currently being assessed in clinical trials for GBM.
- To discuss the potential of MDM2 inhibitors as monotherapy and in combination treatments.
Main Methods:
- Literature review of preclinical studies and clinical trials involving MDM2 inhibitors.
- Focus on drugs investigated for glioblastoma treatment.
- Analysis of combination therapy strategies with existing treatments and targeted agents.
Main Results:
- Preclinical data suggest MDM2 inhibitors are effective in cell culture and animal models for specific GBM subsets (wild-type TP53 or functional p53).
- Several MDM2 inhibitors have advanced to early-phase clinical trials for GBM.
- Combination therapies with radiation, chemotherapy, and other targeted agents are under exploration.
Conclusions:
- MDM2 inhibitors represent a promising therapeutic avenue for a subset of glioblastoma patients.
- Further clinical investigation is required to confirm the efficacy of MDM2 inhibitors, both as single agents and in combination therapies.
- The development of MDM2 inhibitors is a key focus in the ongoing search for effective glioblastoma treatments.
